IMMUNOTECH-B (06978) has released its interim financial results for the six months ended June 30, 2026, revealing a significant improvement in its bottom line.

During the period, the group recorded other income of 12.597 million yuan, reflecting a modest year-on-year decline of 3.4%. However, the loss attributable to shareholders of the company narrowed considerably to 69.867 million yuan, representing a substantial 45.9% reduction compared to the same period last year.

The company reported a basic loss per share of 0.11 yuan for the six-month reporting period.